Jacobs Levy Equity Management
KRRO icon

Jacobs Levy Equity Management’s Korro Bio KRRO Stock Holding History

Jacobs Levy Equity Management’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,556
Closed -$801K – 1049
2022
Q1 		$801K Buy
7,556
+1,199
+19% +$229K 0.01% 794
2021
Q4 		$1.63M Buy
+6,357
New +$1.93M 0.01% 657

Other funds holding KRRO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management's KRRO Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Korro Bio (KRRO) in Q2 2022, closing a stake of 7,556 shares — an estimated $801K sold.

Jacobs Levy Equity Management first reported a position in KRRO in Q4 2021 and held it in 2 quarters. The position peaked at $1.63M in Q4 2021. 58 funds tracked by Wall St. Rank hold KRRO as of Q2 2022.

  • Jacobs Levy Equity Management reported no remaining Korro Bio position as of Q2 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 7,556 Korro Bio shares in Q2 2022, an estimated $801K.
  • Jacobs Levy Equity Management first reported a position in Korro Bio in Q4 2021 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Korro Bio position peaked at $1.63M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Korro Bio as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.